Shares of Eli Lilly (NYSE:LLY) are down 7.6% today, reflecting market disappointment in the company's adjusted guidance for the fourth quarter of 2024. The pharmaceutical giant expects only $13.5 ...

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

Tech entrepreneur and Tesla (TSLA, Financials) CEO Elon Musk's disclosure of using weight-loss pharmaceuticalsincluding Eli Lilly's (LLY, Financials) Mounjaro and Novo Nordisk's Ozempichas drawn ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

In the new filing, Lilly says it wants to wade into the legal proceedings to “protect its interests and help bring this suit to a swift end.” The company’s lawyers further contend that OFA ...

Eli Lilly and Company (NYSE:LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B. The consensus revenue estimate stands at $13.95B. "While the U.S ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

A Pulitzer Prize-winning cartoonist was arrested Wednesday and accused of possessing dozens of child sex abuse videos, police said. A search warrant was served Wednesday at the home of Darrin Bell, 49 ...

In the time since, though, some analysts have said the reaction is overblown, particularly for weight-loss drugmakers like Wegovy, and Ozempic maker Novo Nordisk and Zepbound maker Eli Lilly.